High Expression of Pyruvate Kinase M2 is Associated with Chemosensitivity to Epirubicin and 5-Fluorouracil in Breast Cancer

被引:47
|
作者
Lin, Yang [1 ]
Lv, Feng [1 ]
Liu, Fangfang [1 ]
Guo, Xiaojing [1 ]
Fan, Yu [1 ]
Gu, Feng [1 ]
Gu, Jun [2 ,3 ]
Fu, Li [1 ]
机构
[1] Tianjin Med Univ, Canc Inst & Hosp, Dept Breast Canc Pathol & Res Lab,Natl Clin Res C, Key Lab Breast Canc Prevent & Therapy,Minst Educ, Tianjin 300060, Peoples R China
[2] SUNY Albany, Wadsworth Ctr, New York State Dept Hlth, Albany, NY 12201 USA
[3] SUNY Albany, Sch Publ Hlth, Albany, NY 12201 USA
来源
JOURNAL OF CANCER | 2015年 / 6卷 / 11期
基金
中国国家自然科学基金;
关键词
Pyruvate kinase M2; breast cancer chemosensitivity; epirubicin; 5-fluorouracil; DRUG-SENSITIVITY TEST; IN-VITRO; PKM2; CULTURE; CHEMOTHERAPY; RESISTANCE; CELLS; INHIBITION; PROGNOSIS; THERAPY;
D O I
10.7150/jca.12719
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background: Pyruvate kinase M2 (PKM2) is the key enzyme in the Warburg effect, and it was recently reported to be involved in the metabolic pathways of chemotherapeutic drugs. However, the role of PKM2 in breast cancer and its influence in the sensitivity to front-line anticancer drugs remains unclear. Methods: In this study, we examined the correlation between the expression of PKM2 and the sensitivity of primary breast cancer cells to anticancer drugs. PKM2 expression was studied by immunohistochemistry using biopsy samples of 296 patients diagnosed with invasive breast carcinoma, and the collagen gel droplet embedded culture-drug sensitivity tests (CD-DST) was conducted to all the patients to detect in vitro chemosensitivity after surgery. Results: We found high PKM2 expression was significantly associated with in vitro chemosensitivity to epirubicin (EPI) (P=0.019) and 5-fluorouracil (5-Fu) (P=0.009) in breast cancer patients. Then we used a small group of neoadjuvant chemotherapy cases to confirm that the higher PKM2 expression, the better pathological response to therapy was obtained in patients treated with EPI-based or EPI plus 5-Fu chemotherapy regimens. Although univariate and multivariate analysis indicated that high PKM2 was a poor independent predictor of progression free survival (PFS) and overall survival (OS) in breast cancer, patients with PKM2 high expression who received EPI-based or EPI plus 5-Fu chemotherapy were found to have a longer PFS (P=0.003, P=0.013) and OS (P=0.003, P=0.004) than patients treated with non-EPI/5-Fu-based regimens, respectively. Conclusions: Our findings confirmed the poor prognosis of high PKM2 expression in breast cancer patients and revealed the predictive value of high PKM2 in the therapeutic response to EPI and 5-Fu. Moreover, our results provide the guidance of individual treatment for breast cancer patients who are foreboded a poor prognosis by the presence of high PKM2 status.
引用
收藏
页码:1130 / 1139
页数:10
相关论文
共 50 条
  • [41] Risk of venous thromboembolism in patients receiving adjuvant chemotherapy with 5-fluorouracil, epirubicin and cyclophosphamide for early breast cancer
    Hoy, Julia
    Neeman, Teresa
    Stuart-Harris, Robin
    Davis, Alison
    ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 2009, 5 (02) : 129 - 136
  • [42] Systemic immune effects of adjuvant chemotherapy with 5-fluorouracil, epirubicin and cyclophosphamide and/or radiotherapy in breast cancer: a longitudinal study
    Fariba Mozaffari
    Christina Lindemalm
    Aniruddha Choudhury
    Helena Granstam-Björneklett
    Mats Lekander
    Bo Nilsson
    Marja-Leena Ojutkangas
    Anders Österborg
    Leif Bergkvist
    Håkan Mellstedt
    Cancer Immunology, Immunotherapy, 2009, 58 : 111 - 120
  • [43] Pyruvate kinase M2 (PKM-2) expression and prognostic significance in glioblastoma patients
    Yavuz, Berrin Benli
    Kilinc, Fahriye
    Kanyilmaz, Gul
    Aktan, Meryem
    JOURNAL OF NEURO-ONCOLOGY, 2023, 165 (3) : 527 - 533
  • [44] Nucleoside diphosphate kinase 2 confers acquired 5-fluorouracil resistance in colorectal cancer cells
    Wen, Shaojia
    Wang, Xun
    Wang, Yamin
    Shen, Jianfeng
    Pu, Junyi
    Liang, Hui
    Chen, Chao
    Liu, Linna
    Dai, Penggao
    ARTIFICIAL CELLS NANOMEDICINE AND BIOTECHNOLOGY, 2018, 46 : S896 - S905
  • [45] Pyruvate kinase M2 (PKM-2) expression and prognostic significance in glioblastoma patients
    Berrin Benli Yavuz
    Fahriye Kilinc
    Gul Kanyilmaz
    Meryem Aktan
    Journal of Neuro-Oncology, 2023, 165 : 527 - 533
  • [46] Progress of Pyruvate Kinase M2 in Hepatocellular Carcinoma-Associated Signaling Pathway
    Wan, Qi
    Zhao, Chunlian
    Zhao, Rui
    TISSUE ENGINEERING PART C-METHODS, 2025, 31 (03) : 101 - 107
  • [47] Pyruvate kinase isozyme M2 and glutaminase might be promising molecular targets for the treatment of gastric cancer
    Kitayama, Kishu
    Yashiro, Masakazu
    Morisaki, Tamami
    Miki, Yuichiro
    Okuno, Tomohisa
    Kinoshita, Haruhito
    Fukuoka, Tatsunari
    Kasashima, Hiroaki
    Masuda, Go
    Hasegawa, Tsuyoshi
    Sakurai, Katsunobu
    Kubo, Naoshi
    Hirakawa, Kosei
    Ohira, Masaichi
    CANCER SCIENCE, 2017, 108 (12): : 2462 - 2469
  • [48] Exploring the diverse role of pyruvate kinase M2 in cancer: Navigating beyond glycolysis and the Warburg effect
    Upadhyay, Saurabh
    Khan, Shumayila
    Hassan, Md. Imtaiyaz
    BIOCHIMICA ET BIOPHYSICA ACTA-REVIEWS ON CANCER, 2024, 1879 (03):
  • [49] Pyruvate kinase M2 (PKM2) expression correlates with prognosis in solid cancers: a meta-analysis
    Zhu, Haiyan
    Luo, Hui
    Zhu, Xuejie
    Hu, Xiaoli
    Zheng, Lihong
    Zhu, Xueqiong
    ONCOTARGET, 2017, 8 (01) : 1628 - 1640
  • [50] Pyrotinib Sensitizes 5-Fluorouracil-Resistant HER2+ Breast Cancer Cells to 5-Fluorouracil
    Yi, Jianing
    Chen, Shuai
    Yi, Pingyong
    Luo, Jinlin
    Fang, Meng
    Du, Yang
    Zou, Lianhong
    Fan, Peizhi
    ONCOLOGY RESEARCH, 2020, 28 (05) : 519 - 531